fbpx
Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

FDA approves Leqselvi (deuruxolitinib) to treat Alopecia areata – Sun Pharma

Written by | 30 Jul 2024

Sun Pharmaceutical Industry announced that the FDA approved Leqselvi (deuruxolitinib) 8 mg tablets for the treatment of adults with severe alopecia areata. Alopecia areata affects around 700,000 people… read more.

New treatment could reverse hair loss caused by an autoimmune skin disease

Written by | 16 May 2024

Researchers at MIT, Brigham and Women’s Hospital, and Harvard Medical School have developed a potential new treatment for alopecia areata, an autoimmune disorder that causes hair loss and… read more.

European Commission approves Litfulo (ritlecitinib) to treat adults and adolescents 12 years of age and older with severe alopecia areata – Pfizer

Written by | 29 Sep 2023

Pfizer Inc. announced that the European Commission (EC) has granted marketing authorization for Litfulo (ritlecitinib) to treat adults and adolescents 12 years of age and older with severe… read more.

CHMP recommends Litfulo, an oral treatment for alopecia areata – Pfizer

Written by | 27 Jul 2023

Pfizer Inc. announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion for Litfulo (ritlecitinib), an oral… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.